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Mesoporous silica particles (MSPs) have attracted increasing interest as supports in the design 19 
of controlled delivery materials. Besides their excellent properties as loading supports (i.e. 20 
large surface area and pore volume), the modification of their external surface with 21 
molecular/supramolecular ensembles allows the design of gated MSPs. Delivery systems based 22 
on gated MSPs show “zero delivery” until an adequate stimulus is present and triggers gate 23 
opening and the cargo is released. Encapsulation of bioactive molecules in gated MSPs may 24 
improve biological stability, facilitate component handling, mask unpleasant sensorial 25 
properties and modulate the bioaccessibility of target molecules along the gastrointestinal 26 
tract. These properties make gated MSPs excellent candidates for encapsulating bioactive 27 
molecules and their subsequent utilization in the formulation of functional foods. This text 28 
highlights the most significant endogenous triggering stimuli that might be applied to design 29 
these site-specific delivery systems, as well as the strategies to develop them. Given the 30 
novelty of using MSPs in the food sector, the benefits and current potential limitations of 31 
employing MSPs in human food have been identified and discussed.   32 




1. Mesoporous silica particles as encapsulation supports  34 
Mesoporous silica particles (MSPs) are structures of silicon dioxide (SiO2) which are arranged 35 
so that they create pores of 2-50 nm (Zhao 2006). The first described porous silica with a 36 
uniform pore size, called folded sheet mesoporous material (FSM-16), was reported by Kuroda 37 
and co-workers in 1990 (Yanagisawa and others 1990). A few years later, in 1992, researchers 38 
of the Mobil Company reported the synthesis of a family of mesoporous silica materials called 39 
M41S (Beck and others 1992), which include hexagonal MCM-41, cubic MCM-48 and lamellar 40 
MCM-50.  41 
Since its discovery, applications of MSPs have grown exponentially as a result of their unique 42 
properties. Specifically, MSPs have demonstrated to have huge applications in the food sector, 43 
where they could be employed as catalysts in the synthesis of nutrients and bioactive 44 
molecules (Márquez-Ávarez and others 2004), in sensor technology (Climent and others 2009) 45 
and also as carriers in the design of smart delivery systems (Bernardos and others 2008, Pérez-46 
Esteve and others 2015). Of these applications, the design of smart delivery systems is viewed 47 
as challenging given the possibility of improving the handling and utilization of different 48 
bioactive molecules or functional ingredients, and the subsequent formulation of functional 49 
food (Bernardos and Kourimská 2013).  50 
Although there is neither a regulatory nor a standard definition of “functional foods” (Aryee 51 
and Boye 2015), this term refers to the foods and food components that may offer health 52 
benefits beyond basic nutrition (Bech-Larsen and Grunert 2003). The terms food components 53 
and bioactive ingredients with beneficial biological activity include basic nutrients (i.e. 54 
carbohydrates, proteins, lipids, vitamins, minerals, etc.), bioactive components (i.e., omega-3 55 
fatty acids, amino acids and peptides, and phytochemicals), sensory appeal compounds (i.e. 56 
organic acids, flavors and pigments), as well as pre- and probiotics, healthy oils, spices and 57 
herbs (Fang  and Bhandari 2012). 58 
Despite the increase in functional products in markets and the scientific literature, the 59 
incorporation of these functional ingredients into existing food formulations is still viewed as 60 
challenging. On the one hand, most studies on the functionality of food compounds have been 61 
done in vitro, which thus excludes studying changes in potential active compounds during food 62 
processing, storage, ingestion and interaction with gut microflora. On the other hand, some 63 
bioactive components are most complicated to be handled or are not compatible with the 64 
food matrix in terms of solubility (lipophilic compounds), sensorial properties (i.e. fish oils or 65 
garlic extracts), or are very susceptible to degradation (vitamins, antioxidants). The desire to 66 
overcome these limitations has increased the interest in the encapsulation of bioactive 67 
components because after encapsulation, they could be released in a particular site-of-action 68 
of the digestive tract and/or be absorbed in their native form, which thus avoids problems 69 
related to instability or to unpleasant sensory properties (McClements 2012).  70 
Typically, food applicable encapsulating systems are based on carbohydrates, proteins or lipids 71 
(Fathi and others 2012; Wang and others 2012; Fathi and others 2014). However, these 72 
systems exhibit low structure stability while food is processed and stored, a poor capability to 73 
control the release rate or to provide a targeted delivery, and a very poor effect on the 74 




problems could be avoided if mesoporous silica particles (MSPs) are used as encapsulating 76 
supports. Compared to other organic polymer-based carriers, MSPs are more stable, rigid and 77 
biocompatible. They also better resist the harsh conditions of the stomach and microbial 78 
attack. MSPs are also able to protect entrapped guest molecules against enzymatic 79 
degradation or denaturation induced by pH or temperature (Arcos and Vallet-Regí 2013). 80 
This review critically assesses the possible use of mesoporous silica materials to design site-81 
specific smart delivery systems capable of encapsulating, protecting, transporting and 82 
releasing bioactive molecules in a controlled fashion in the gastrointestinal tract (GIT). 83 
2. Fabrication of gated MSPs 84 
2.1 Synthesis and features of the inorganic support 85 
MSPs are synthesized using two main elements: a) a template whose function is to direct the 86 
construction of the high ordered (crystalline) porous net; b) a polymeric precursor which self-87 
organizes around the template and, upon polymerization, builds up the final rigid structure. 88 
Synthesis starts with the polymerization, in an aqueous solution, of the inorganic siliceous 89 
precursor (i.e. tetraethyl orthosilicate) around surfactant micelles (i.e. N-90 
cetyltrimethylammonium bromide -CTAB-). The mesoporous inorganic scaffold obtained under 91 
these conditions presents cylindrical unidirectional empty channels of approximately 3 nm in 92 
diameter (when CTAB is used as a surfactant), arranged in a hexagonal distribution. 93 
Mesoporous materials are obtained by the subsequent removal of the surfactant by extraction 94 
with adequate solvents, or by aerobic high temperature calcination (500-600ºC) (Hoffman and 95 
others 2006). Figure 1 schematically represents the complete synthesis procedure. 96 
 97 
Figure 1. Schematic representation of the synthesis of mesoporous silica particles by structure-98 
directing agents 99 
 100 
Minor changes in the synthesis route make it possible to modify final key features in the solid 101 
to produce other types of mesoporous silica, such as hexagonal mesoporous silica (HMS) 102 
(Tanev and Pinnavaia 1995), Michigan State University material (MSU) (Bagshaw and others 103 
1995), Santa Barbara Amorphous Silica (i.e. SBA-15) (Zhao and others 1998 a,b), Technische 104 
Universiteit Delft material (i.e. TUD-1) (Jansen and others 2001), Universidad Valencia Material 105 
(i.e. UVM-7) (el Haskouri and others 2002), and a wide variety of hollow silica spheres (Li and 106 
others 2004; Zhang and others 2009; Cao and others 2013). TEM and FESEM pictures of some 107 





Figure 2. TEM and FESEM images of different mesoporous silica particles.  110 
 111 
Given the potential application of MSPs to develop oral controlled delivery systems, different 112 
attempts to synthesize MSPs from food-like precursors have been successfully made.  On the 113 
one hand, rice husk ashes have been employed as a silica source for the synthesis of different 114 
mesoporous silicas (Jang and others 2009; Bhagiyalakshmi 2010). On the other hand, 115 
polyglycerol esters of fatty acids, myristic acid ester of pentaglycerol and oleic acid have also 116 
been employed as food grade structures directing agents (Kapoor and others 2010; Han and 117 
others 2011; Ishii and others 2012).  118 
In any case, different MSPs share their composition, which is based on a SiO2-network, an 119 
ordered mesostructure and the presence of silanol groups on the particle surface. Some differ 120 
from others in size, shape, porous size and volume, specific surface area and density of silanol 121 
groups on the surface to provide different surface charges (Pérez-Esteve and others 2014). The 122 
morphology and porosity of different MSPs are determined by processing parameters: type of 123 
surfactant template, silica source, pH, temperature, aging time, additives, and solvents (Kierys 124 
and others 2010). The textural properties of different MSPs have been previously revised and 125 
compared in different publications (Wang and others 2011; Wright 2008). 126 
In general, MSPs stand out for being supports that can be synthesized with a controlled size 127 
from 50 nm to a few microns. This range in size is important in scope. While small MSPs can 128 
cross epitheliums and can be distributed in the body to be non specifically internalized by 129 
certain cells, oversized particles cannot easily cross physical membranes in the body. As 130 
particle size has been demonstrated to play a key role in the distribution and behavior of 131 
particles in living systems, large particle sizes are preferred for developing orally administrated 132 
controlled release devices (Arcos and Vallet-Regí 2013).  133 
MSPs can also be synthesized with uniform tunable porosity. Pore size can be tailored between 134 
2-10 nm (Aznar and others 2009a). The presence of a mesoporous network provides large 135 
surface areas (700-1000 m2g-1) and a great loading capacity compared to large pore volumes 136 
(0.6-1 cm3g-1) (Colilla and others 2013). Pore size, pore volume and a proper surface charge are 137 
essential for encapsulating a sufficiently large amount of a certain bioactive component and 138 
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silica is governed by size and charge selectivity. Only the molecules with a size smaller than the 140 
porous size of the silica support can be entrapped by the porous structure (Arcos and others 141 
2013). Other factors that determine adsorption and the release kinetics of a bioactive 142 
compound in a certain media are pore length and pore ordering (Izquierdo-Barba and others 143 
2009a; Burguete and others 2012), particle morphology (Manzano and others 2008), surface 144 
area (Balas and others 2006), macroscopic form (Izquierdo-Barba, 2009b) and modification or 145 
functionalization of the silica surface with functional groups (Nieto and others 2008).  146 
Finally, the surface of MSPs can be easily functionalized with molecular/supramolecular 147 
ensembles to develop gated MSPs that show “zero delivery” and are capable of releasing their 148 
cargo on-command in response to specifically designed external stimuli (Mondragón and 149 
others 2014). These unique features of MSPs make them excellent candidates for developing 150 
smart delivery systems. 151 
 152 
2.2 Functionalization of MSPs to develop triggered delivery systems 153 
The surface of MSPs presents a high concentration of structural defects in the form of silanol 154 
(Si-OH) groups that can easily react with trialkoxysilane derivatives ((R’O)3-Si-R) and allow the 155 
possibility of generating organic−inorganic hybrid materials (Vinu and others 2005).  156 
In this area, one appealing concept is the development of “molecular gates”. Molecular or 157 
supramolecular gates are defined as nanoscopic supramolecular-based devices that are 158 
attached to certain solid supports, in which mass transport can be triggered by a target 159 
external stimulus that can control the state of the gate (closed or open) at will (Aznar and 160 
others 2009). In particular, and depending on the type of stimulus applied, it is possible to 161 
modify the properties of anchored molecules (i.e. polarity, conformation, size, interaction with 162 
other species, bond hydrolysis etc.) which, in turn, results in controlled delivery (Coll and 163 
others 2007, Casasús and others 2008, Aznar and others 2009b, Bernardos and others 2012). A 164 
schematic representation of a gate-like superstructure is shown in Figure 3. 165 
 166 
Figure 3. Schematic representation of the operation principle of a molecular gate in a 167 
mesoporous support. Molecular gates (orange lines) hinder the release of a guest molecule 168 
(yellow spheres) entrapped in the mesoporous supports (gray container) since a suitable 169 





As observed, smart delivery systems based on gated MSPs contain two components: a suitable 172 
inorganic support which acts as a nanocontainer (for loading the cargo); a switchable “gate-173 
like” ensemble capable of being opened or closed when certain external stimuli are applied. 174 
Both components are important, and their selection determines the controlled release 175 
performance of the hybrid support (Bernardos and others 2010; Burguete and others 2012).  176 
The first example of a molecular gate was reported by Fujiwara and co-workers in 2003 (Mal 177 
and others 2003). Since then, a number of gated systems that have used mesoporous silica 178 
supports which respond to a wide variety of stimuli have been described (Aznar and others 179 
2009a; Coll and others 2013; Arcos and Vallet-Regí 2013).  180 
 181 
3. Design of site-specific delivery systems that act along the gastrointestinal tract through 182 
gated MSPs 183 
As previously stated, the encapsulation and later administration of bioactive molecules at a 184 
particular site-of-action of the digestive tract (mouth, stomach, intestine or colon) offer huge 185 
possibilities to develop new functional foods or medical therapies. Hence the design of 186 
systems capable of controlling the release of basic nutrients, bioactive components, sensory 187 
appeal compounds, and pre- and probiotics, and even drugs, is a very challenging strategy that 188 
can be easily achieved by using capped MSPs. 189 
When designing a site-specific delivery system based on hybrid organic-inorganic supports, 190 
there are two factors that should be taken into account. On the one hand, the porous system 191 
of the inorganic support should be able to entrap the target molecule. On the other hand, the 192 
capping molecule should be responsive to a triggering stimulus, and is present in a particular 193 
cavity of the gastrointestinal tract. Moreover, it must remain unchanged in the cavities that 194 
proceed. An overview of these stimuli is provided in Figure 4.  195 
 196 
Figure 4. Summary of the chemical and biological stimuli able to trigger capped-MSPs during 197 




This section describes the suitable stimuli found along the gastrointestinal tract that could be 199 
employed in developing site-specific delivery systems and all the approaches developed to 200 
date to design molecular gates responsive to these stimuli. 201 
 202 
3.1 A brief physicochemical description of the digestive system 203 
3.1.1 Mouth 204 
Gastrointestinal tract activity begins in the mouth where the ingested food is chewed and 205 
mixed with saliva to allow bolus formation and to enhance taste (Humphrey and Williamson 206 
2001; Chen 2009). Saliva is a complex heterogeneous clear fluid (pH 5.6-7.6) that consists in 207 
roughly 98% water and 2% organic and inorganic substances, including electrolytes, mucus, 208 
glycoproteins, proteins, antibacterial compounds, enzymes, and others (Levine and others 209 
1987).  210 
Of all the enzymes contained in saliva, α-amylase is the most important. The interaction of 211 
amylase with starch-based ingredients produces a breakdown of starch into simpler sugars (i.e. 212 
maltose and dextrins), which can be further broken down in the small intestine. Despite this 213 
enzymatic action of saliva, it should be stated that salivary α-amylase is most active at its 214 
optimum pH of 7.4, and is inactivated in the stomach because of gastric acid. Thus even 215 
though enzyme interaction begins almost immediately after food ingestion, its contribution to 216 
full starch breakdown is relatively insignificant. Most starch digestion results from pancreatic 217 
amylase rather than from salivary amylase (Chen 2009). Salivary glands also secrete salivary 218 
lipase that starts the degradation of dietary triglycerides into fatty acids and diglycerides that 219 
start with fat digestion. However, salivary lipase does not play a digestive role in adult humans. 220 
Recent studies have suggested that it plays only a role in fat taste and texture perception 221 
(Drewnowski and Almiron-Roig 1997).  222 
The residence time in the oral cavity is short, and varies by 2-5 min seconds depending on 223 
saliva swallowing and water intake. Thus the main suitable triggering stimuli in the buccal 224 
cavity are pH (neutral) and presence of α-amylase and salivary lipase. However, due to the 225 
short residence time and low enzyme activity, the influence of the mouth on the action of 226 
molecular gates could be considered negligible. 227 
3.1.2 Stomach 228 
Once food is swallowed, it passes into the stomach. In the stomach, food stuffs find gastric 229 
juice secretion. Gastric juice provides a harsh environment characterized by a very acid media 230 
(pH 1-2) that is rich in electrolytes, proteases (pepsin, renin and gastric lipase) and lipases 231 
(Chiras 2015). Microflora in the stomach is predominantly Gram-positive and aerobic, and the 232 
bacterial concentration is usually <103 colony-forming units CFU/mL (Campieri and Gionchetti, 233 
1999). The redox potential in the stomach is +150 mV (Friend 1992). The residence time of 234 
food in the stomach depends on the digestibility of meals; while light meals based on 235 
carbohydrates may be ready to pass into the small intestine through the pyloric valve in 2 h, 236 
heavy meals that contain proteins and fats may require up to 6 h to perform the same action. 237 




dietary fat has been hydrolyzed (Krohn and others 2008). The digestion process is thus 239 
completed in the small intestine.  240 
3.1.3 Small intestine 241 
In the small intestine, the hydrolysis of all the majority food structures and macronutrients 242 
occurs by the combined action of small intestine and accessory organs (pancreas and liver) 243 
secretions.  244 
Once the chyme arrives to the duodenum, the pancreas secretes pancreatic juice. Pancreatic 245 
juice is a liquid that contains water, sodium chloride, sodium bicarbonate and a number of 246 
digestive enzymes (i.e. amylases, lipases, proteases, ribonucleases and deoxyribonucleases) 247 
that help finish the digestive process that started in the stomach. Sodium bicarbonate 248 
neutralizes the high acidity of the chyme. In this manner, the duodenum pH is 6.0 (within the 249 
5.7-6.2 range) and gradually increases through the small intestine to pH 7.5 (within the 7.3-7.7 250 
range) (Fallingborg 1999). This difference with the stomach pH allows the design of pH-251 
responsive devices. The enzymatic profile of pancreatic juice is completed by enzymes of 252 
microvilli that constitute the brush border (i.e. saccharidases, peptidases and nucleases). 253 
Working together, both types of enzymes are able to hydrolyze almost all large molecules into 254 
absorbable food components.  255 
The duodenum also receives a fluid though the bile duct which is produced in the liver and 256 
stored in the gallbladder, and is known as bile. Bile is composed of water, cholesterol, lecithin 257 
(a phospholipid), bile pigments (with no digestive function), bile salts (sodium glycocholate and 258 
sodium taurocholate) and bicarbonate ions. The powerful surfactant activity of bile 259 
components helps with the digestion and adsorption of lipophilic components.  260 
Regarding microflora, the proximal small bowel is similar to that of the stomach. The bacterial 261 
concentration is 103-104 CFU/mL. However, the distal ileum is able to support anaerobic 262 
bacterial flora. Consequently, the concentration of microorganisms increases in the distal 263 
ileum to levels of 105-109 CFU/mL and the redox potential in the small intestine lowers from -264 
50 mV in the duodenum or jejunum to -150 mV in the ileum (Friend 1992; Campieri and 265 
Bionchetti 1999).   266 
After this complete digestive process, which lasts between 2-5 h, most food structures have 267 
been disintegrated into absorbable molecules. Undigested food remains pass through the 268 
ileocaecal valve to the large intestine. 269 
3.1.4 Large intestine 270 
The large intestine, which comprises the caecum, colon and rectum, is the last part of the 271 
digestive tract. Its main objectives are to absorb the water and electrolytes that escape from 272 
absorption in the small intestine, and to store and remove feces during defecation. 273 
Understanding the last part of the GIT offers different possibilities to design triggered 274 
responsive MSPs for controlled release in the large intestine. 275 
The large intestine pH varies according to the food ingested. In general, the pH in the 276 




length. The transverse colon exhibits a pH of 7.4, descending colon, pH 7.5, sigmoidal colon, pH 278 
7.4, and rectum, pH 7.2. The shallow pH gradient between the small intestine and the colon 279 
does not allow the design of colonic delivery drug carriers based on pH changes (Milabuer and 280 
others 2010). 281 
However, the large intestine is the natural habitat for a huge microbial community. The colon 282 
contains 1011 to 1012 CFU/mL. Predominant species include Bacteroides, Bifidobacterium and 283 
Eubacterium. Anaerobic gram-positive cocci, as well as Clostridium, enterococci, and various 284 
species of Enterobacteriaceae are also present. It allows us to talk about a final digestion stage 285 
carried out by a wide variety of metabolic processes, including fermentation, enzyme-286 
mediated reactions, and the reduction of a wide range of organic functional groups. Among 287 
the different extracellular enzymes produced by colonic bacteria, azoreductases, 288 
oxidoreductases, ureases, dextranases and a number of saccharidases capable of breaking 289 
indigestible carbohydrates, stand out.  290 
The total metabolic and bacterial activity in the large intestine generates a characteristic redox 291 
potential (-200 mV) that can be used as a highly selective mechanism for targeting in the colon 292 
(Friend 1992; Chourasia and Jain 2003). The residence time in the large intestine ranges from 293 
2–72 h. In most individuals, mouth-to-anus transit times are usually longer than 24 h. More 294 




Table 1. Summary of suitable digestive stimuli for designing triggered MSPs-based delivery systems 296 
 Chemical Enzymatic 
  Enzyme Substrate Origin 
Mouth Neutral pH α-amylase (ptyalin) Starch Salivary glandules 
  Salivary lipase Triacylglicerids Salivary glandules 
Stomach Acid pH  Gastric lipase  Triacylglicerids Gastric chief cells 
  Pepsin Proteins and polipeptids Gastric chief cells 
  Renin Casein Gastric chief cells 
Small intestine Neutral/basic pH Chymotrypsin 
(endopeptidase) 
Proteins (endopeptidase) Pancreas 
 Bile acids (cholic and 
deoxycholic acid) 
Carboxypeptidase A & B 
(exopeptidase) 
Proteins  Pancreas 
 Phospholipids Cholesterol esterase Cholesterol esters Pancreas 
  Colipase Favours the action of the lipase Pancreas 
  Deoxyribonuclease Deoxyribonucleic acid (DNA) Pancreas 
  Elastase Elastin fibres Pancreas 
  fructofuranosidase 
(Sucrase or Isomaltase) 
Sucrose Brush border 
  Pancreatic α-amylase Starch Pancreas 
 Pancreatic lipase Fat and triglycerides Pancreas  
 Phospholipase A2 Phospholipids Pancreas  
  Ribonuclease Ribonucleic acid (RNA) Pancreas 
  Trypsin (endopeptidase) Proteins  Pancreas 
  -1-4 galactosidase (Lactase) Lactose  Brush border 
  -glucosidase (Maltase)  Maltose Brush border 
  -limit dextrinase Limit dextrines Brush border 
  Nucleosidase Nucleosides Brush border 





Large intestine Basic pH -L-arabinosidase -L-arabinofuranosides, 
arabinoxylans and arabinogalactans 
Colonic bacteria 
 Redox potential Azoreductases Azo (N=N) bonds Colonic bacteria 
 
  Dextranase Dextran Colonic bacteria 
  -D-galactosidase β-D-galactosides (i.e. 
galactooligosaccharides) 
Colonic bacteria 
  -D-glucosidase β-glucosides (i.e. cellulose and 
hemicellulose) 
Colonic bacteria 
  -glucuronidase β-D-glucuronic acid residues Colonic bacteria 
 
  Oxidoreductase Transfer of electrons (i.e. pyruvate 
oxidation) 
Colonic bacteria 
  Polysaccharidases Indigestible polysaccharides (i.e. 
amylose, chitosan, dextrans…) 
Colonic bacteria 
  Urease Urea Colonic bacteria 
  -D-xylosidase β-D-xylans, xylobiose Colonic bacteria 
 




3.2 Strategies to develop site-specific smart delivery devices 297 
After discussing the most significant digestive stimuli that could be used to design capped 298 
MSPs for controlled release purposes in the gastrointestinal tract, the current MSP-based 299 
systems that can be opened using these triggering principles are presented in this section. 300 
3.2.1 pH-responsive molecular gates 301 
The first strategy to develop pH-responsive gated materials was based on using ionizable 302 
simple molecules anchored to the material surface, which undergo conformational and/or 303 
solubility changes in response to environmental pH variation, which modifies its conformation. 304 
Based on this approach, Martínez-Máñez and co-workers developed the first pH-driven 305 
molecular gate in 2004 (Casasús and others 2004). Their mechanism was based on the 306 
protonation/deprotonation processes of polyamines grafted onto the pore outlets of the 307 
mesoporous inorganic scaffolds. At an acid pH, the columbic repulsions between the 308 
protonated amino groups hinders pore access (gate closed), while at a neutral pH, 309 
unprotonated amines tend to interact with each other, which favors pore access (gate open). 310 
Figure 5 illustrates the action mechanism of this reversible smart delivery system. Bearing in 311 
mind all these concepts, Bernardos and others (2008), developed the first controlled release 312 
system mediated by a gastrointestinal stimulus. Given the objective of protecting riboflavin 313 
from acidic stomach conditions and of releasing the load in the intestine, these authors 314 
encapsulated vitamin riboflavin in an MCM-41 type support and functionalized its surface with 315 
the described pH-controlled gate-like scaffolding. They found a zero release under the 316 
stomach-like conditions (acid pH, gate closed) and a time-modulated delivery under the 317 
intestine-like conditions (neutral pH, gate open). 318 
 319 
Figure 5. Schematic representation of a pH-driven molecular gate-like material based on the 320 
use of polyamines. Amines (orange lines) are protonated at a low pH. Deprotonation favors 321 
coloumbic repulsions among different chains and coordination with anionic species (blue dots) 322 
than block pores. Under this condition, the guest molecule (yellow spheres) cannot escape 323 
from the porous support (gray container). At a neutral, pH amines are unprotonated, which 324 
allows cargo delivery. 325 
A second strategy involved modifying the chemical interactions among the molecules 326 
covalently anchored to the surface of the mesoporous silica as a result of changes in pH. 327 




nanoparticles loaded with sulfasalazine (an anti-inflammatory prodrug used for bowel disease) 329 
functionalized with trimethylammonium functional groups via the direct co-condensation of a 330 
trimethylammonium silane. Undert acidic conditions, the cargo remained inside the voids of 331 
the porous support. However under neutral conditions, the deprotonation of the silanol 332 
groups generated a strong electrostatic repulsion, which triggered the sustained release of the 333 
loaded molecules. 334 
The third strategy comprised the design of devices capped with molecules anchored with acid-335 
sensitive bonds, whose cleavage enabled the release of cargo molecules. By bearing this 336 
principle in mind, Zhao and others (2010) developed a pH-responsive nanoparticle capable of 337 
being opened under acid conditions. The design strategy involved using mesoporous silica 338 
nanoparticles loaded with rhodamine B and functionalized with -cyclodextrins through imine 339 
double bonds. The β-cyclodextrin rings on the surface of nanoparticles served as gates to store 340 
cargo molecules (i.e., rhodamine B) inside the nanopores of nanoparticles under neutral 341 
conditions. At an acidic pH the cleavable imine bonds that attached -cyclodextrines to the 342 
particle’s surface were hydrolyzed and the cargo was released.   343 
Besides polyamines, trymetylammonium groups and cyclodextrins, other capping molecules 344 
(such as polymers, peptides, proteins and DNA) have been used as gatekeepers in pH-triggered 345 




Table 2. Selected examples of gated materials responsive to changes in pH. 347 
Gating molecule or system Closed Opened Cargo Suitable delivery 
location 
Reference 
Carboxylic acid Neutral Acid Vancomycin Stomach Yang and others 2005 
Chitosan Neutral  Acid Ibuprofen Stomach Popat and others 2012a 
-cyclodextrine Neutral Acid Propidium iodide Stomach Du and others 2009 
-cyclodextrine Neutral Acid Rhodamine B Stomach Guo and others 2010 
Peptide K8 Neutral  Acid Doxorubicin Stomach Luo and others 2013 
Polydopamine Neutral  Acid Doxorubicin Stomach Zheng and others 2014 
Poly(4-vinyl pyridine) Neutral Acid Tris(bipyridine)ruth
enium(II) chloride 
Stomach Liu et al 2011 
3-aminopropyltrimethoxysilane and 4-
sulfophenyl isothiocyanate 
Acid  Neutral Ibuprofen Small Intestine Cauda and others 2010 
β-lactoglobulin Acid Neutral Ibuprofen Small Intestine Guillet-Nicolas and others 
2013 
Bovine serum albumin conjugated with 
lactobionic acid 
Acid  Neutral Doxorubicin Small Intestine Luo and others 2012 
Hydroxypropyl methylcellulose phthalate Acid  Neutral Famotidine Small Intestine Xu and others 2009 




Oligonucleotide Acid  Neutral/Basic Rhodamine B Small Intestine Chen and others 2011 
Poly(acrylic acid) Acid Neutral/Basic Salidroside Small Intestine Peng and others 2013 






Small Intestine Casasús and others 2004 
Casasús and others 2008 
 
Bernardos and others 
2008 
Pérez-Esteve and others 
2015 
Trimethylammonium groups Acid Neutral Sulfasalazine Small Intestine Lee and others 2008 
Cheng and others 2011 




3.2.2 Redox-responsive molecular gates 348 
As occurred with changes in pH, the evolution of the redox potential along the gastrointestinal 349 
tract might allow the design of redox-driven gated mesoporous materials, especially for colon-350 
targeted delivery. To date, no specific system based on naturally-occurring changes in redox 351 
potential changes along the GI to modulate the delivery of bioactive molecules has been 352 
provided. However, there are a number of approaches that could be the basis for future 353 
developments.  354 
Lai and others (2003) prepared a controlled delivery system to encapsulate several 355 
pharmaceutical drug molecules and neurotransmitters inside an organically functionalized 356 
mesoporous silica framework. In particular, this nano-device was prepared using MCM-41-type 357 
mesoporous silica nanospheres as an inorganic support and cadmium sulfide (CdS) 358 
nanocrystals as chemically removable caps. Addition of disulfide-reducing molecules, such as 359 
dithiothreitol (DTT) and mercaptoethanol (ME), to the aqueous suspension of the particles 360 
triggered a rapid release of the mesopore-entrapped cargo by breaking the chemically labile 361 
disulfide linkages between the MSP and CdS nanoparticles. Also based on disulfide linkages, Liu 362 
and others (2008) prepared a calcined MCM-41 solid support loaded with dye molecules, with 363 
the surface functionalized by the grafting of a poly(N-acryloxysuccinimide). The openings of 364 
the resulting hybrid material remained blocked due to the cross-linked reaction between the 365 
N-oxysuccimide groups along the polymer chain and the cystamine of the media. In contrast, 366 
the presence of disulfide-reducing agents, such as (DTT) cleavage of the disulfide bond of 367 
cystamine, induced pore opening and controlled dye release.  368 
A different approach was published by Hernandez and others (2004). These authors described 369 
the use of an MCM-41 mesoporous scaffold loaded with an iridium complex dye and 370 
functionalized with a 1,5-dioxynaphtalene derivative (DNPD) as a redox-responsive delivery 371 
system. The addition of cyclobis-(paraquat-p-phenylene) (CBPQT4+) induced the formation of a 372 
pseudorotaxane on the external surface of the solid. This new non covalent supramolecular 373 
ensemble blocked pores and prevented dye delivery. When a reductive agent was added to 374 
the mixture (cyanoborohydride in this case), the reduction in DPND started a spontaneous 375 
dethreading of the CBPQT4+ ring to allow guest release. The evolution of that gated system was 376 
the achievement of a total reversible hybrid material capable of being open or closed on 377 
command in a reversible manner. In this case, Nguyen and others (2005) firstly synthesized a 378 
[2]rotaxane-containing DNPD and a tetrathiafulvalene moiety (TTF) as a redox centre to link 379 
each other through a oliogoethylenglycol chainRotaxane was completed by the presence of a 380 
rigid spacer and a CBPQT4+ as the movable molecule. Preference for CBPQT4+ for TTF or DNPD 381 
groups as a result of the oxidation state of TTF (dependent on the addition of oxidant or 382 
reducing species) caused gate movement, which changed from a closed to an open 383 
conformation.  384 
 385 
 3.2.3 Surfactant-responsive molecular gates 386 
The surfactant-induced molecular gates concept was introduced by Giménez and others 387 




surface with 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). The presence of DOPC created 389 
a lipid bilayer around pore outlets that inhibited cargo release. However, the system released 390 
its cargo after the addition of dodecyltrimethylammonium bromide (DTAB), a single-chain 391 
cationic surfactant whose activity is similar to phosphocholine (lecithin).  392 
 393 
3.2.4 Enzyme-responsive molecular gates 394 
The wide variety of enzymes present along the gastrointestinal tract, and their selective 395 
location (stomach, brush border, colon,) allowed the design of very specific site release 396 
systems. One of the first examples of gated MSPs capable of delivering an entrapped cargo in 397 
the presence of saccharases was described by Bernardos and others (2009). These authors 398 
designed a mesoporous silica particle capped with a covalently anchored lactose derivative. 399 
Cargo delivery from aqueous suspensions was negligible because the formation of a dense 400 
network of lactose groups linked through the hydrogen-bonding interaction around pore 401 
outlets. The addition of -D-galactosidase enzyme (lactase) induced progressive cargo release, 402 
which was clearly related to the enzymatic hydrolysis of the glycosidic bond in disaccharide 403 
lactose. This is a clear example of the potential use of an enzyme-responsive molecular gate to 404 
hinder cargo release during food processing, storage and the first part of the digestion in the 405 
stomach, and one that is able to release the guest molecule in the small intestine in the 406 
presence of enzymes of brush border mucosa. 407 
In line with this, the same authors functionalized the surface of a loaded MCM-41 support with 408 
three different commercially available hydrolyzed starches (Glucidex 47, 39 and 29) via the 409 
derivatization of starch with an alkoxysilane. Cargo release was achieved by enzymatic 410 
hydrolysis in the presence of pancreatin (an enzyme cocktail that contains pancreatic amylase), 411 
which showed different release kinetics according to the the degree of starch hydrolysis 412 
(Figure 6). The lower the hydrolysis rate of starch, the lower the delivery rate (Bernardos and 413 
others 2010). 414 
 415 
Figure 6. Schematic representation of an enzyme-driven molecular gate-like material 416 
functionalized with hydrolyzed starch. In the absence of pancreatin, starch derivatives (orange 417 
chains) hinder the release of the guest molecule (yellow spheres) from the porous support 418 
(gray container) by steric hindrance. In the presence of amylases, starch is hydrolyzed, which 419 




Bein and co-workers prepared the first molecular gate opened by the presence of a protease 421 
(Schlossbauer and others 2009). Capping systems consisted in attaching avidin to a 422 
biotinylated MSP. The addition of protease trypsin induced the hydrolysis of the attached 423 
avidin and cargo release. Along the same lines, Coll and others (2011) employed a click 424 
chemistry reaction to functionalize the external surface of an MSP with a peptide to develop a 425 
nanodevice capable of hampering cargo release. Delivery was observed in the presence of 426 
proteases (Figure 7). 427 
 428 
Figure 7. Schematic representation of an enzyme-driven molecular gate-like material capped 429 
with a peptide. In the absence of proteases, peptidic chains (dot chains) hinder the release of 430 
the guest molecules (yellow spheres) from the porous support (gray container) by steric 431 
hindrance. In the presence of peptidases, peptides are hydrolyzed and payload is delivered. 432 
 433 
Some examples of deoxyribonuclease-triggered delivery systems have also been reported. Zhu 434 
and coworkers presented an oligodeoxynucleotide-capped material using hollow MSPs that 435 
was opened in the presence of DNase I (Zhu and others 2011a). Zhang and others (2014) 436 
reported the use of a porous material loaded with the drug colchicine and capped with 437 
oligodeoxynucleotides that was able to be uncapped also when DNase I was used. 438 
The possibility of using enzymes secreted from colonic microflora to design smart delivery 439 
systems has been previously reported. Agostini and others (2012a) described an ethylene 440 
glycol-capped hybrid material for the controlled release of a certain cargo in the presence of 441 
esterase. In the absence of an esterase enzyme, the steric hindrance imposed by bulk ester 442 
glycol moieties inhibited cargo release. Upon the addition of the esterase enzyme, cargo 443 
delivery occurred due to the hydrolysis of the ester bond, which reduced the of the glycol 444 
derivative. In another work, the same authors prepared MSPs loaded with Rhodamine B and 445 
functionalized with an alkylgluconamine derivative of a galacto-oligosaccharide (GOS) capable 446 
of delivering its cargo in the presence of -galactosidase (Agostini and others 2012b). Mas and 447 
others (2013) reported the synthesis of a hybrid material capped with an azopyridine 448 




to display cargo release in the presence of azo-reductases, which are usually present in the 450 
colon.  451 
More examples of enzyme-responsive gated materials are shown in Table 3.  The profound 452 
analysis of all the reported examples allowed a conclusion to be drawn that the most extended 453 
enzymes used as triggering stimuli are amylases, proteases, peptidases and 454 
deoxyribonucleases (which can be used for delivery in the small intestine) and reductases, 455 
esterases and ureases (which can be used for controlled cargo delivery in the colon). However, 456 
the real development of enzyme-responsive gated materials with applications in the design of 457 
site-specific delivery systems that act along the gastrointestinal tract is still in its incipient 458 




Table 3. Selected examples of gated materials responsive to the presence of target enzymes. 460 
Gating molecule or system 
 
Closed Opened Cargo Suitable delivery 
location 
Reference 
Avidin–biotin complex Absence of trypsin Presence of trypsin Fluorescein Small intestine Schlossbauer and others 
2009 
Bioactive peptide shell Absence of thermolysin 
and elastase 





Small intestine Thornton and Heise, 2010 
 β-cyclodextrin  Absence of α-amylase and 
lipase 
Presence of α-amylase 
and lipase 
 Calcein Small intestine Park and others2009 





Small intestine Bernardos and others 
2010 






Small Intestine Bernardos and others 
2009 




Fluorescein Small intestine Zhu and others 2011a 
Peptide sequence Absence of peptidases or 
acid pH 
Presence of peptidases 
and neutral pH 
Tris(bipyridine)ruth
enium(II) chloride 
Small Intestine Coll and others 2011 








Protamine Absence of trypsin Presence of trypsin Diclofenac Small intestine Radhakrishnan and others 
2014 




Colchicine Small intestine Zhang and others 2014 
α-cyclodextrin included onto a 
polyethyleneglycol fragment 
Absence of esterase Presence of bacterial 
esterases 
Rhodamine B Colon Patel and others2008 
Azobenzene-4,4’-dicarboxylic acid Absence of azo-reductase Presence of bacterial azo-
reductase 
Ibuprofen Colon Li and others 2014 
Azopyridine derivative Absence of azo-
reductases and esterases 
Presence of bacterial azo-
reductases and esterases 




Absence of urease Presence of bacterial 
ureases 
Rhodamine B Colon Sun and others 2013 




Colon Agostini and others 2012a 




Rhodamine B Colon Agostini and others 2012b 
Sulfasalazine Absence of bacterial azo-
reductase 
Presence of bacterial azo-
reductase 
 Sulfasalazine Colon Popat and others 2012b 





3.2.5 Dual stimuli-controlled release 463 
One step forward in the design of gated mesoporous supports is the possibility of preparing 464 
gated materials that could be opened by using two different stimuli. For instance, Casasús and 465 
others (2008) studied pH- and anion-responsive gated-like ensembles in anion complex 466 
formation terms with polyamines. This study came to the conclusion that larger anions pushed 467 
tethered polyamines toward pore openings and reduced the pore aperture. More recently, 468 
Popat and others (2014) reported the use of silica nanoparticles that were responsive to 469 
multiple digestive stimuli (pH and enzymes). Their system consisted of an MCM-48-type 470 
structure loaded with sulfasalazine, and functionalized with amino groups coated with a 471 
succinylated soy protein isolate (SSPI). The resultant delivery system showed both pH and 472 
enzyme responsiveness, depending on the location of the nanoparticles in the GIT. In both the 473 
stomach and duodenum, the low environmental pH (pH 1.2 and ca. 5, respectively) restricted 474 
the release of sulfasalazine due to the capping effect of the SSPI. In contrast, when the delivery 475 
system reached the small intestine (pH 7.4) the change in pH induced the hydrolyzate 476 
destabilization, which favors protein hydrolysis by the pancreatin enzyme. The result was a 477 
controlled, slow and sustained drug release in the small intestine.  478 
 479 
4. Benefits and potential current limitations of MSPs for their use in human food  480 
As previous proved, delivery systems based on hybrid organic-inorganic MSPs show most of 481 
the desired properties for a smart delivery system: high loading capacity, controlled release 482 
rate of a bioactive molecule at a particular site in response to a particular trigger, good 483 
biocompatibility, low-cost fabrication given its composition and easy handling, etc. Yet given  484 
its novelty, some limitations (toxicological, technological, semantic, legal and sociological) still 485 
need to be overcome, which should be solved before starting to use MSP-based smart delivery 486 
systems in food and nutrition.  487 
4.1 Toxicological: lack of conclusive studies 488 
Despite silica not being considered harmful for humans, it is known that engineered 489 
nanomaterials are not governed by the same laws as larger particles (Pérez-Esteve and others 490 
2013). If we bear in mind that change in size affects the functionality of particles, it could also 491 
affect people exposed to newly developed particles. In this context, in recent years, several 492 
studies have addressed the toxicological and biocompatibility properties of MSPs.  493 
The impact of nanoparticles general lydepends on certain properties, such as particle size, size 494 
distribution, shape, solubility, reactivity, mass, chemical composition, surface properties (area 495 
and charge) and aggregation state (Chau and others 2007; Athinarayanan and others 2014).  496 
He and others (2009) studied the effect of particle size (nano- and microparticles), 497 
concentration, biodegradation products, and residual surfactant on the cytotoxicity of human 498 
breast-cancer cell lines (MDA-MB-468) and African green monkey kidney cell lines (COS-7). 499 




concentrations above 25 mg/mL, while microscale particles of 1220 nm showed only slight 501 
cytotoxicity due to reduced endocytosis. In line with this in an in vivo study with male nude 502 
mice, Souris and others (2010) confirmed that after oral administration, silica nanoparticles 503 
located in the liver could be excreted into the intestine by the hepatobiliary excretion process. 504 
Later, Fu and others (2013) demonstrated with female ICR mice that silica nanoparticles (110 505 
nm in size) are absorbed into the body at 24 h of oral administration. Yet once absorbed, 506 
particles are transported via the portal vein to the liver and are then eliminated during a 7-day 507 
period by fecal excretion, and also through urine, without changing the kidney microstructure. 508 
These results agree with the studies done into tissue distribution and excretion kinetics of 509 
orally administered silica nanoparticles in rats carried out by Lee and others (2014). These 510 
authors reported that after ingestion, particles are distributed to kidneys, liver, lungs and 511 
spleen. However, silica particles are easily decomposed and eliminated via urinary and fecal 512 
excretion after oral exposure. The smaller the particles, the more rapidly they are secreted, 513 
presumably because they are more easily decomposed.  514 
As well as particle size, particle shape seems important when talking about potential 515 
toxicology. Tao and others (2008) evaluated the effect of two types of mesoporous silica 516 
particles on mitochondrial O2 consumption. For this purpose, the effect of SBA-15 (irregular 517 
rods of ca. 1000 nm in length and aspect ratio of 1:5) and MCM-41 (spheres of 300-1000 nm in 518 
diameter) on mitochondrial O2 consumption (respiration) was evaluated in HL-60 (myeloid) 519 
cells, Jurkat (lymphoid) cells, and isolated mitochondria. These authors observed that while 520 
SBA-15 inhibited cellular respiration at 25-500 μg/mL, MCM-41 had no noticeable effect on the 521 
respiration rate.  522 
Finally, surface properties also seem relevant for potential toxicology (Tang and others 2012). 523 
Specifically, van Schooneveld and others (2008) reported the improved biocompatibility and 524 
pharmacokinetics of silica nanoparticles by means of a lipid coating. In their extensive study on 525 
bare and lipid-coated silica nanoparticles in mice, these authors concluded that coating porous 526 
silica with organic molecules can increase the biocompatibility and half-lives of cells by more 527 
than 10-fold compared to bare silica mesoporous supports.  528 
Thus despite adverse effects having been observed in some cells or animals treated with 529 
different concentrations of some MSPs, other in vitro and in vivo studies have suggested that 530 
certain particles are well tolerated by both cells and superior animals. Therefore, it is hard to 531 
draw conclusive conclusions about the biocompatibility and toxicity of MSPs as a unique 532 
concept. In any case, the use of mesoporous silica microparticles functionalized on their 533 
surface with biocompatible organic molecules seems a good strategy to minimize the risks 534 
associated with using MSPs as supports to develop smart delivery systems.  535 
 536 
4.2 Technological problems: mass production and impact of MSPS-based delivery systems on 537 
the food matrix 538 
There is no doubt that the application of MSP-based delivery systems to the formulation of 539 




launching foods that contain MSPs to the market, some technological problems should be 541 
solved.  542 
First, one problem is related with the mass production of MSPs. To date, processes for the 543 
synthesis, loading and functionalization of MSPs are being developed on a laboratory scale. As 544 
a result, production costs are high and mass production is practically underdeveloped.  545 
The second technological problem is related to the compatibility of these devices with the 546 
food matrix. Generally, introducing new ingredients or additives to a food matrix can affect the 547 
physico-chemical and sensory properties of the product. However, it is considered that a 548 
delivery system suitable for a particular application should be compatible with the food or 549 
beverage matrix that it is to be incorporated into, and should cause no adverse effects on 550 
product appearance, flavor, texture, mouth feel or shelf life.  551 
Despite the importance of this aspect, as far as we know, there is only one publication that has 552 
dealt with determining the influence of MSPs on physical properties of the food matrix to 553 
which they could be included (Pérez-Esteve and others 2014). However, since MSPs have a 554 
high load capacity and bioactive compounds exhibit their functional properties at very low 555 
concentrations, it is assumed that the amount of support needed to release an adequate 556 
concentration of the component is very low. Thus it is foreseeable that the physicochemical 557 
features of the matrix that is to incorporate these supports should not be affected by the 558 
presence of encapsulating systems.  559 
 560 
4.3 Semantic: Disharmonized and changing and denominations 561 
As previously described, the MSPs concept involves structures of silicon dioxide (SiO2) arranged 562 
in such a way that they are able to create pores of 2-50 nm. This structure on the nanoscale is 563 
the key to design molecular or supramolecular capped materials. Its design, fabrication, 564 
manipulation and characterization are possible thanks to nanotechnology. Therefore, should 565 
MSPs be considered nanomaterials? It is clear that mesoporous silica nanoparticles are 566 
nanomaterials. But what happens with mesoporous silica microparticles? By taking into 567 
account only European recommendations and regulations, denominations are disharmonized 568 
and have changed over the years. 569 
Regulation (EC) No. 1169/2011, on the provision of food information to consumers, defined 570 
the engineered nanomaterial concept as intentionally produced materials that have one 571 
dimension or more in the order of 100 nm, or less, or is composed of discrete functional parts, 572 
either internally or on the surface, many of which have one dimension or more in the order of 573 
100 nm, or less, including structures, agglomerates or aggregates, whose size above the order 574 
may be 100 nm, but retain characteristic properties of the nanoscale. Characteristic of the 575 
nanoscale includes: (i) those related to the large specific surface area of the materials 576 
considered; and/or (ii) the specific physico-chemical properties that differ from those of the 577 
non nanoform of the same material. According to this definition, and regardless of size, MSPs 578 




chemical properties and to create nanoporous structures to increase their specific surface 580 
area. 581 
In the same year, the European Commission defined nanomaterials as natural, incidental or 582 
manufactured material that contains particles, in an unbound state, or as an aggregate or 583 
agglomerate, where for > 50% of the particles in the number size distribution, one external 584 
dimension or more falls within the 1 nm-100 nm size range (EU 2011). This definition is in line 585 
with the opinion of the Scientific Committee on Emerging and Newly Identified Health Risks 586 
(SCENIHR), included the size distribution of a material as a defining element, and excludes 587 
other types of nanostructured materials, such as nanoporous or nanocomposite materials, 588 
since there is not enough evidence to guide what materials should be included. 589 
These definitions, apart from being technical, affect regulatory aspects and food labeling. Thus, 590 
they are vital for the future of these systems. The NanoDefine Project (FP7) is expected to 591 
deliver an implementable test scheme for regulatory purposes to distinguish nano from non 592 
nanomaterials by 2017. 593 
 594 
4.4  Legal: Lack of specific regulations 595 
According to their composition (SiO2), MSPs should be authorized for use in food. SiO2 is 596 
“Generally Recognized as Safe” (GRAS) by FDA regulations. It is also an authorized additive in 597 
Europe and achieves the E-551 classification (Contado and others 2013). In the food industry, 598 
synthetic amorphous silica has been used for many years to clear beers and wines, as an anti-599 
caking agent to maintain the flow properties of powder products, and as a carrier agent for 600 
flavorings and aromas, and to thicken pastes.  601 
However when we consider their physical features, MSPs could be classified as novel food 602 
ingredients based on engineered nanomaterials. Thus in order to place a specific MSP as a 603 
food ingredient in the Community market, the applicant should submit a request to the 604 
Member State in which the product would be placed (Regulation (EC) No. 258/97). If approved, 605 
the presence of the engineered nanomaterial should be clearly indicated in the list of 606 
ingredients by writing the word “nano” in brackets (Regulation (EC) No. 1169/2011).  607 
4.5 Sociological: in the face of the unknown, the precautionary principle 608 
The uncertainty in purely semantic aspects and in conclusive toxicological studies has not only 609 
consequences at a regulatory level, but also influences consumers’ risk perception and 610 
acceptance. Although very little research has been conducted in developing countries on 611 
consumer attitudes toward foods that contain nanostructured ingredients, recent studies 612 
point out that lack of information about the impact of nanotechnology on environmental and 613 
health consequences leads consumers to apply the precautionary principle and, therefore, to 614 
reject such products (Chau and others 2007). 615 
For novel foods to be accepted, consumers must perceive that any potential benefits outweigh 616 




environment, human and animal health, or ethical concerns, such as animal welfare or social 618 
equity) (Frewer and Fischer 2010).  619 
For this to happen, information about the potential benefits and potential risks should not only 620 
be accurate, but also very clear. This entails properly regulating the use of nanotechnologies in 621 
food and publishing conclusive studies about the potential risks of each type of MSP by 622 
considering all the variables that can affect their toxicity. Until this time comes, 623 
generalizations, doubts or risk perceptions will outweigh the real benefits.   624 
5. Conclusions 625 
Gated MSPs have the potential to encapsulate bioactive molecules and, consequently, to 626 
protect them from the environment during production, storage and digestion, to mask their 627 
odor and taste, to improve their compatibility with the food matrix, and to amend their 628 
bioaccessibility along the GIT. This review reports the most recent research into the design of 629 
gated mesoporous siliceous materials for controlled release along the GIT using physiologic 630 
stimuli. It also highlights the possibilities of naturally-occurring stimulus along the GIT that 631 
could be used to develop new gated systems. Applications for these capped materials can be 632 
found in the design of novel functional foods. Nevertheless, given their novelty, the 633 
incorporation of gated-MSPs into food still poses major challenges (i.e. technological, 634 
toxicological, legal, sociological, etc.) that need to be overcome by researchers and regulatory 635 
bodies. Researchers have the task of evaluating the potential hazards of MSPs-gated systems 636 
in human health and the environment, and to design specifically designed systems to be 637 
triggered in the gastrointestinal tract. Regulatory bodies should provide specific regulations 638 
and criteria to be followed when evaluating the safety of this new smart delivery system to be 639 
used in food applications. Collaborative work from those groups will be essential in 640 
forthcoming years to generate confidence in industry and consumers. Only then will functional 641 
foods developed by this new technology be available in the food chain.  642 
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